GO:0106342 omega-hydroxyceramide biosynthetic process: Skin Barrier Lipid Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106342 describes the biosynthesis of omega-hydroxyceramide/acylceramide, a specialized epidermal sphingolipid required for the corneocyte lipid envelope.
• The pathway involves omega-hydroxylation of ultralong-chain fatty acids, ceramide synthase-mediated amide bond formation, and lipoxygenase-mediated release of omega-hydroxyceramide for covalent attachment to corneocyte proteins.
• Key enzymes include cytochrome P450 family 4 members (CYP4F22), ceramide synthases (CERS3), fatty acid transport protein 4 (FATP4/SLC27A4), and arachidonate lipoxygenases (ALOX12B, ALOX15B).
• Defects in omega-hydroxyceramide biosynthesis cause severe skin barrier disorders such as congenital ichthyosis and are linked to psoriasis and atopic dermatitis.
• Research tools include lipidomics, transcriptional profiling, CRISPR knockout models, and immunofluorescence imaging of corneocyte lipid envelope formation.
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to study genes in this pathway.
Description
Omega-hydroxyceramide biosynthetic process (GO:0106342) is the metabolic route that produces omega-hydroxyceramides, a unique class of sphingolipids in which the fatty acid moiety is hydroxylated at the terminal omega carbon. These lipids are essential for the skin permeability barrier because they are covalently attached to corneocyte surface proteins, forming the corneocyte lipid envelope. The pathway is highly active in the epidermis and involves coordinated action of fatty acid transporters, cytochrome P450 omega-hydroxylases, ceramide synthases, and lipoxygenases. Researchers study this process to understand skin barrier formation, epidermal differentiation, and the molecular basis of ichthyosis and inflammatory skin diseases. The QuickGO definition states that GO:0106342 encompasses the chemical reactions and pathways resulting in the formation of omega-hydroxyceramide/acylceramide. This article integrates authoritative ontology data with verified PubMed literature to provide a research-grade overview of the pathway, its genes, disease relevance, and experimental models.
omega-hydroxyceramide biosynthetic process At A Glance
| GO ID | GO:0106342 |
|---|---|
| GO term | omega-hydroxyceramide biosynthetic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Biosynthesis of omega-hydroxyceramide/acylceramide, a key lipid for the corneocyte lipid envelope and skin barrier |
| Pathway context | Epidermal sphingolipid metabolism; lipoxygenase-hepoxilin pathway |
| Key enzymes | CYP4F22, CERS3, ALOX12B, ALOX15B, FATP4/SLC27A4 |
| Tissue specificity | Predominantly epidermis, especially differentiated keratinocytes |
| Disease relevance | Congenital ichthyosis, psoriasis, atopic dermatitis |
What Is GO:0106342?
GO:0106342 omega-hydroxyceramide biosynthetic process is defined as the chemical reactions and pathways resulting in the formation of omega-hydroxyceramide/acylceramide. In practice, this means the enzymatic steps that convert precursor fatty acids and sphingoid bases into ceramides bearing an omega-hydroxyl group on the N-acyl chain. These omega-hydroxyceramides are then available for further processing, including covalent attachment to corneocyte proteins during epidermal barrier formation.
Why Is omega-hydroxyceramide biosynthetic process Important in Cell Biology?
Omega-hydroxyceramide biosynthesis is critical for the skin permeability barrier, which protects against water loss and environmental insults. The corneocyte lipid envelope, formed by omega-hydroxyceramide covalently bound to corneocyte proteins, is a unique structure essential for barrier function. Defects in this pathway cause severe skin diseases, including congenital ichthyosis and inflammatory conditions such as psoriasis. Understanding the biosynthetic process provides insights into epidermal differentiation and potential therapeutic targets for skin disorders.
• Essential for skin permeability barrier and water retention.
• Required for corneocyte lipid envelope formation.
• Mutations in pathway genes cause congenital ichthyosis.
• Altered in psoriatic lesions and atopic dermatitis.
• Involves unique omega-hydroxylation of ultralong-chain fatty acids.
• Lipoxygenases mediate release of omega-hydroxyceramide for covalent attachment.
• Vitamin C stimulates sphingolipid production and barrier formation in keratinocytes.
• Target for research in epidermal lipidomics and barrier repair.
• Provides models for studying lipid metabolic disorders.
• Potential applications in cosmetic and dermatological therapeutics.
What Happens During omega-hydroxyceramide biosynthetic process?
Fatty Acid Uptake and Omega-Hydroxylation
In simple terms: First, cells take up long-chain fatty acids and add a hydroxyl group at the far end.
The pathway begins with the transport of ultralong-chain fatty acids into epidermal cells, mediated by fatty acid transport protein 4 (FATP4/SLC27A4). These fatty acids undergo omega-hydroxylation, primarily catalyzed by cytochrome P450 family 4 enzymes such as CYP4F22, converting them to omega-hydroxy fatty acids. This step is essential for generating the unique omega-hydroxyl group characteristic of omega-hydroxyceramides.
Ceramide Synthesis
In simple terms: The omega-hydroxy fatty acid is then linked to a sphingoid base to form a ceramide.
Omega-hydroxy fatty acids are conjugated to sphingoid bases by ceramide synthases, particularly CERS3, to form omega-hydroxyceramides. This amide bond formation occurs in the endoplasmic reticulum and is a key committed step in the pathway. The resulting omega-hydroxyceramide can then be further processed for barrier formation.
Lipoxygenase-Mediated Release and Covalent Attachment
In simple terms: Enzymes called lipoxygenases help release the omega-hydroxyceramide so it can attach to the outside of skin cells.
Lipoxygenases such as ALOX12B and ALOX15B mediate the release of omega-hydroxyceramide from the corneocyte lipid envelope, facilitating its covalent attachment to corneocyte proteins. This process is part of the lipoxygenase-hepoxilin pathway, which is crucial for epidermal barrier formation. The covalent binding of omega-hydroxyceramide to proteins like involucrin and loricrin forms the corneocyte lipid envelope.
Regulation by Vitamin C and Differentiation
In simple terms: Vitamin C and cell differentiation signals boost the production of these barrier lipids.
Vitamin C stimulates sphingolipid production and markers of barrier formation in submerged human keratinocyte cultures. Epidermal differentiation also upregulates the expression of genes involved in omega-hydroxyceramide biosynthesis, ensuring that the barrier is formed in the outermost skin layers.
Key Genes Involved in GO:0106342 omega-hydroxyceramide biosynthetic process
The following genes and proteins are experimentally implicated in omega-hydroxyceramide biosynthetic process and related epidermal barrier pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP4F22 | Omega-hydroxylation of ultralong-chain fatty acids | Mutations cause ichthyosis; target for lipidomics |
| CERS3 | Ceramide synthase for omega-hydroxyceramide formation | Essential for skin barrier; knockout models |
| ALOX12B | Lipoxygenase mediating omega-hydroxyceramide release | Linked to congenital ichthyosis |
| ALOX15B | Lipoxygenase in epidermal barrier formation | Potential role in omega-hydroxyceramide processing |
| SLC27A4 (FATP4) | Fatty acid transport protein 4 | Required for incorporation of ultralong-chain fatty acids |
| ABCA12 | Lipid transporter in lamellar bodies | Associated with ichthyosis; affects ceramide transport |
| TGM1 | Transglutaminase 1 cross-links proteins | Corneocyte envelope formation |
| LOR | Loricrin, corneocyte envelope protein | Covalent attachment of omega-hydroxyceramide |
| IVL | Involucrin, corneocyte envelope protein | Covalent attachment of omega-hydroxyceramide |
| SPTLC1 | Serine palmitoyltransferase subunit | Sphingolipid synthesis upstream |
| SPTLC2 | Serine palmitoyltransferase subunit | Sphingolipid synthesis upstream |
| CERS4 | Ceramide synthase | May compensate for CERS3 |
| ELOVL4 | Elongation of very long-chain fatty acids | Provides ultralong-chain fatty acids |
| PNPLA1 | Patatin-like phospholipase domain containing 1 | Transacylase for omega-hydroxyceramide |
| CYP4A11 | Omega-hydroxylase | Potential redundancy with CYP4F22 |
| ALOXE3 | Epidermis-type lipoxygenase 3 | Part of lipoxygenase pathway |
| FADS2 | Fatty acid desaturase 2 | Essential fatty acid metabolism |
| SPTSSA | Serine palmitoyltransferase small subunit A | Regulates sphingolipid synthesis |
How Is omega-hydroxyceramide biosynthetic process Regulated?
The omega-hydroxyceramide biosynthetic process is regulated at multiple levels. Transcriptional regulation occurs during epidermal differentiation, with increased expression of CYP4F22, CERS3, and ALOX12B in differentiated keratinocytes. Vitamin C stimulates sphingolipid production and barrier formation in keratinocyte cultures. The lipoxygenase-hepoxilin pathway is also regulated by essential fatty acids and calcium-dependent signaling. Additionally, fatty acid availability and transport via FATP4 influence substrate supply for omega-hydroxylation.
omega-hydroxyceramide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP4F22 | Congenital ichthyosis | CRISPR knockout keratinocytes; lipidomics |
| CERS3 | Ichthyosis; skin barrier defect | Knockout mouse; 3D skin equivalents |
| ALOX12B | Congenital ichthyosis | Point mutation knock-in; lipoxygenase activity assays |
| ABCA12 | Harlequin ichthyosis | Knockout models; lipid transport studies |
| PNPLA1 | Ichthyosis; omega-hydroxyceramide transacylation | Knock-in of patient mutations; lipidomics |
Congenital Ichthyosis
Mutations in genes involved in omega-hydroxyceramide biosynthesis, such as CYP4F22, CERS3, ALOX12B, and ALOXE3, cause autosomal recessive congenital ichthyosis, characterized by defective skin barrier and scaling. These mutations impair the formation of the corneocyte lipid envelope, leading to severe water loss and skin abnormalities.
Psoriasis
Lipidomic and transcriptional analysis of psoriatic lesions reveals alterations in the linoleoyl-omega-hydroxyceramide biosynthetic pathway, suggesting that dysregulation of omega-hydroxyceramide production contributes to psoriasis pathology. The inflammatory environment may affect lipoxygenase activity and ceramide composition.
Atopic Dermatitis
Atopic dermatitis is associated with impaired skin barrier function, often linked to reduced levels of omega-hydroxyceramides and other barrier lipids. Defects in the lipoxygenase-hepoxilin pathway have been implicated in the pathogenesis of atopic dermatitis.
From omega-hydroxyceramide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate omega-hydroxyceramide levels? | CRISPR knockout in human keratinocytes followed by lipidomics |
| What is the catalytic mechanism of CYP4F22? | Point mutation knock-in of active site residues; enzyme assays |
| How does a disease mutation affect barrier formation? | Knock-in of patient mutation in 3D skin equivalents |
| Where is the protein localized during differentiation? | Tagged knock-in with fluorescent protein; imaging |
| Does overexpression of CERS3 enhance barrier lipids? | Overexpression in keratinocytes; lipid profiling |
| Which genes are essential for corneocyte lipid envelope? | CRISPR library screening in epidermal cells |
How to Study the omega-hydroxyceramide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Omega-hydroxyceramide species and abundance | Quantify pathway activity in cells/tissues |
| RNA-seq | Transcript levels of pathway genes | Identify transcriptional regulation |
| qPCR | Expression of specific genes | Validate differentiation-dependent expression |
| Immunofluorescence | Protein localization and lipid envelope formation | Visualize corneocyte lipid envelope |
| CRISPR knockout | Loss-of-function effects on lipid profile | Determine gene necessity |
| CRISPR knock-in | Effect of disease mutations | Model ichthyosis mutations |
| Overexpression | Gain-of-function effects | Test sufficiency of enzymes |
| CRISPR library screening | Identify novel regulators | Unbiased discovery of pathway genes |
Lipidomics and Mass Spectrometry
Lipidomic analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for quantifying omega-hydroxyceramide species in cells and tissues. This method can detect changes in chain length, hydroxylation, and saturation, providing direct evidence of pathway activity.
Transcriptional Profiling
RNA sequencing and quantitative PCR are used to measure expression of genes involved in omega-hydroxyceramide biosynthesis, such as CYP4F22, CERS3, and ALOX12B, during keratinocyte differentiation or in disease models.
Immunofluorescence and Imaging
Immunofluorescence microscopy with antibodies against corneocyte envelope proteins or tagged lipids can visualize the formation and localization of the corneocyte lipid envelope in skin equivalents and tissue sections.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and overexpression models enable causal testing of candidate genes in the pathway. Pooled CRISPR screens coupled with lipidomics or barrier assays can identify novel regulators of omega-hydroxyceramide biosynthesis.
How CRISPR Can Be Used to Study GO:0106342 omega-hydroxyceramide biosynthetic process
Knockout
CRISPR knockout of genes such as CERS3, CYP4F22, or ALOX12B in human keratinocytes or mouse models abolishes omega-hydroxyceramide production, leading to defective skin barrier formation. These models are essential for establishing causal roles and for testing compensatory pathways.
Point Mutation
Introducing patient-specific point mutations (e.g., in CYP4F22 or ALOX12B) via CRISPR knock-in allows researchers to study the molecular consequences of disease-associated variants on enzyme activity and lipid profiles.
Knock-in
Knock-in of tagged versions of pathway enzymes (e.g., GFP-CERS3) enables live-cell imaging and proteomic analysis of protein interactions and localization during differentiation.
Overexpression
CRISPR activation or cDNA overexpression of rate-limiting enzymes such as CERS3 or CYP4F22 can boost omega-hydroxyceramide levels, providing gain-of-function models to test sufficiency and therapeutic potential.
How EDITGENE Supports omega-hydroxyceramide biosynthetic process Research
Researchers studying omega-hydroxyceramide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, barrier formation, or disease. EDITGENE provides comprehensive CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for omega-hydroxyceramide biosynthetic process research.
Frequently Asked Questions About omega-hydroxyceramide biosynthetic process
What is omega-hydroxyceramide biosynthetic process?
It is the metabolic pathway defined by GO:0106342 that produces omega-hydroxyceramides, specialized sphingolipids essential for the skin barrier.
What genes are involved in omega-hydroxyceramide biosynthetic process?
Key genes include CYP4F22, CERS3, ALOX12B, ALOX15B, and SLC27A4 (FATP4).
What diseases are linked to omega-hydroxyceramide biosynthesis?
Defects cause congenital ichthyosis and are associated with psoriasis and atopic dermatitis.
How is omega-hydroxyceramide biosynthetic process regulated?
It is regulated by epidermal differentiation, vitamin C, and essential fatty acids.
What is the role of lipoxygenases in omega-hydroxyceramide biosynthesis?
Lipoxygenases such as ALOX12B mediate the release of omega-hydroxyceramide for covalent attachment to corneocyte proteins.
Which enzymes catalyze omega-hydroxylation in this pathway?
Cytochrome P450 family 4 enzymes, particularly CYP4F22, catalyze omega-hydroxylation of ultralong-chain fatty acids.
What is the corneocyte lipid envelope?
It is a lipid-protein structure formed by omega-hydroxyceramide covalently bound to corneocyte proteins, essential for skin barrier function.
How can I study omega-hydroxyceramide biosynthesis in the lab?
Use lipidomics, transcriptional profiling, and CRISPR knockout/knock-in models in keratinocytes.
What cell models are suitable for omega-hydroxyceramide research?
Human keratinocytes, 3D skin equivalents, and CRISPR-engineered cell lines are commonly used.
Does vitamin C affect omega-hydroxyceramide production?
Yes, vitamin C stimulates sphingolipid production and markers of barrier formation in keratinocyte cultures.
Conclusion
Omega-hydroxyceramide biosynthetic process (GO:0106342) is a specialized lipid pathway critical for skin barrier function and epidermal differentiation. Its dysregulation leads to severe skin diseases, making it a key area of dermatological research. By combining QuickGO ontology data with verified PubMed literature, this article provides a comprehensive resource for researchers. EDITGENE offers advanced CRISPR tools to dissect this pathway and accelerate discoveries in skin biology.
References
- 1. Tyrrell VJ et al.. 2021. Lipidomic and transcriptional analysis of the linoleoyl-omega-hydroxyceramide biosynthetic pathway in human psoriatic lesions.. J Lipid Res 62:100094 PMID: 34171322
- 2. Zheng Y et al.. 2011. Lipoxygenases mediate the effect of essential fatty acid in skin barrier formation: a proposed role in releasing omega-hydroxyceramide for construction of the corneocyte lipid envelope.. J Biol Chem 286(27):24046-56 PMID: 21558561
- 3. Lin MH et al.. 2019. Fatty acid transport protein 4 is required for incorporation of saturated ultralong-chain fatty acids into epidermal ceramides and monoacylglycerols.. Sci Rep 9(1):13254 PMID: 31519952
- 4. Wertz PW. 1997. Integral lipids of hair and stratum corneum.. EXS 78:227-37 PMID: 8962495
- 5. Wertz PW. 2025. A Provocation on Formation of the Corneocyte Lipid Envelope.. Skin Pharmacol Physiol 38(4):159-164 PMID: 40623411
- 6. Wertz PW. 2021. Lipid Metabolic Events Underlying the Formation of the Corneocyte Lipid Envelope.. Skin Pharmacol Physiol 34(1):38-50 PMID: 33567435
- 7. Muñoz-Garcia A et al.. 2014. The importance of the lipoxygenase-hepoxilin pathway in the mammalian epidermal barrier.. Biochim Biophys Acta 1841(3):401-8 PMID: 24021977
- 8. Uchida Y et al.. 2001. Vitamin C stimulates sphingolipid production and markers of barrier formation in submerged human keratinocyte cultures.. J Invest Dermatol 117(5):1307-13 PMID: 11710949
